Epigenetic Regulation of Apoptosis in Cutaneous T-Cell Lymphoma: Implications for Therapy with Methotrexate, Jak Inhibitors, and Resveratrol

J Invest Dermatol. 2022 Feb;142(2):493-496.e7. doi: 10.1016/j.jid.2021.06.034. Epub 2021 Aug 3.

Authors

Minakshi Nihal¹, Jianqiang Wu², Connor J Stonesifer³, Jay Daniels⁴, Jaehyuk Choi⁴, Larisa Geskin³, Alain H Rook⁵, Gary S Wood²

Affiliations

¹ Department of Dermatology, The School of Medicine and Public Health, University of Wisconsin and William S. Middleton VAMC, Madison, Wisconsin, USA. Electronic address: mnihal@dermatology.wisc.edu.
² Department of Dermatology, The School of Medicine and Public Health, University of Wisconsin and William S. Middleton VAMC, Madison, Wisconsin, USA.
³ Department of Dermatology, Irving Medical Center, Columbia University, New York, New York, USA.
⁴ Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
⁵ Department of Dermatology, Penn Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Acetylation / drug effects
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Apoptosis / drug effects
Apoptosis / genetics
Epigenesis, Genetic / drug effects*
Gene Expression Regulation, Neoplastic / drug effects
Humans
Janus Kinase Inhibitors / pharmacology
Janus Kinase Inhibitors / therapeutic use
Lymphoma, T-Cell, Cutaneous / drug therapy*
Lymphoma, T-Cell, Cutaneous / genetics
Lymphoma, T-Cell, Cutaneous / pathology
Methotrexate / pharmacology
Methotrexate / therapeutic use
Protein Processing, Post-Translational / drug effects
Resveratrol / pharmacology
Resveratrol / therapeutic use
Skin Neoplasms / drug therapy*
Skin Neoplasms / genetics
Skin Neoplasms / pathology

Substances

Janus Kinase Inhibitors
Resveratrol
Methotrexate

Grants and funding